首页> 外文期刊>BMC Cancer >Bioinformatics analysis of C3 and CXCR4 demonstrates their potential as prognostic biomarkers in clear cell renal cell carcinoma (ccRCC)
【24h】

Bioinformatics analysis of C3 and CXCR4 demonstrates their potential as prognostic biomarkers in clear cell renal cell carcinoma (ccRCC)

机译:C3和CXCR4的生物信息学分析证明了它们作为透明细胞肾细胞癌(CCRCC)的预后生物标志物的潜力

获取原文
获取外文期刊封面目录资料

摘要

The molecular prognostic biomarkers of clear cell renal cell carcinoma (ccRCC) are still unknown. We aimed at researching the candidate biomarkers and potential therapeutic targets of ccRCC. Three ccRCC expression microarray datasets (include GSE14762, GSE66270 and GSE53757) were downloaded from the gene expression omnibus (GEO) database. The differentially expressed genes (DEGs) between ccRCC and normal tissues were explored. The potential functions of identified DEGs were analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). And then the protein - protein interaction network (PPI) was established to screen the hub genes. After that, the expressions of hub genes were identified by the oncomine database. The hub genes’ prognostic values of patients with ccRCC were analyzed by GEPIA database. A total of 137 DEGs were identified by utilizing the limma package and RRA method, including 63 upregulated genes and 74 downregulated genes. It is found that 137 DEGs were mainly enriched in 82 functional terms and 24 pathways in accordance with the research results. Thirteen highest-scoring genes were screened as hub genes (include 10 upregulated genes and 3 downregulated candidate genes) by utilizing the PPI network and module analysis. Through integrating the oncoming database and GEPIA database, the author found that C3 and CXCR4 are not only overexpressed in ccRCC, but also associated with the prognosis of ccRCC. Further results could reveal that patients with high C3 expression had a poor overall survival (OS), while patients with high CTSS and TLR3 expressions had a good OS; patients with high C3 and CXCR4 expressions had a poor disease-free survival (DFS), while ccRCC patients with high TLR3 expression had a good DFS. These findings suggested that C3 and CXCR4 were the candidate biomarkers and potential therapeutic targets of ccRCC patients.
机译:透明细胞肾细胞癌(CCRCC)的分子预后生物标志物仍然未知。我们旨在研究CCRCC的候选生物标志物和潜在的治疗目标。三个CCRCC表达式微阵列数据集(包括GSE14762,GSE66270和GSE53757)从基因表达式omnibus(Geo)数据库下载。探讨了CCRCC和正常组织之间的差异表达的基因(DEGS)。通过基因本体(GO)和基因组和基因组(KEGG)的基因本体(GO)和Kyoto百科全书分析了鉴定的DEG的潜在功能。然后建立蛋白质 - 蛋白质相互作用网络(PPI)以筛选轮毂基因。之后,通过oncomine数据库鉴定了轮毂基因的表达。通过Gepia数据库分析了CCRCC患者的轮毂基因预后值。通过利用LiMMA包和RRA方法鉴定总共137次,其中包括63个上调基因和74个下调基因。发现,根据研究结果,137只主要富集82个功能术语和24个途径。通过利用PPI网络和模块分析,将十三个最高评分基因筛选为枢纽基因(包括10个上调基因和3个下调的候选基因)。通过集成迎面而来的数据库和GEPIA数据库,作者发现C3和CXCR4不仅在CCRCC中过表达,而且与CCRCC的预后相关。进一步的结果可以揭示高C3表达的患者的整体存活率差(OS),而高CTS和TLR3表达的患者具有良好的操作系统;高C3和CXCR4表达的患者具有较差的无病生存(DFS),而CCRCC患者具有高TLR3表达的患者具有良好的DFS。这些发现表明C3和CXCR4是CCRCC患者的候选生物标志物和潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号